Towards Label-Free Brain Tumor Segmentation: Unsupervised Learning with Multimodal MRI
Gerard Comas-Quiles, Carles Garcia-Cabrera, Julia Dietlmeier, Noel E. O'Connor, Ferran Marques
TL;DR
This work tackles label-free brain tumor segmentation by casting anomaly detection as learning a healthy-prior model from multimodal MRI. It introduces the Multimodal Vision Transformer Autoencoder (MViT-AE) that reconstructs healthy brain MRIs and localizes tumors via reconstruction errors, enhanced by a multimodal early-late fusion strategy and a SAM-based postprocessing stage. The method yields lesion-wise DSCs of ET, NET, SNFH, TC, and WT on BraTS-GoAT 2025, with a 89.4% anomaly Detection Rate on the validation set, demonstrating competitive unsupervised performance and potential scalability across tumor types. Despite challenges such as detecting small or hypointense lesions and the dependence on postprocessing, the approach shows promise for label-efficient neuro-oncological imaging and lays groundwork for future representation learning and semi-supervised refinements.
Abstract
Unsupervised anomaly detection (UAD) presents a complementary alternative to supervised learning for brain tumor segmentation in magnetic resonance imaging (MRI), particularly when annotated datasets are limited, costly, or inconsistent. In this work, we propose a novel Multimodal Vision Transformer Autoencoder (MViT-AE) trained exclusively on healthy brain MRIs to detect and localize tumors via reconstruction-based error maps. This unsupervised paradigm enables segmentation without reliance on manual labels, addressing a key scalability bottleneck in neuroimaging workflows. Our method is evaluated in the BraTS-GoAT 2025 Lighthouse dataset, which includes various types of tumors such as gliomas, meningiomas, and pediatric brain tumors. To enhance performance, we introduce a multimodal early-late fusion strategy that leverages complementary information across multiple MRI sequences, and a post-processing pipeline that integrates the Segment Anything Model (SAM) to refine predicted tumor contours. Despite the known challenges of UAD, particularly in detecting small or non-enhancing lesions, our method achieves clinically meaningful tumor localization, with lesion-wise Dice Similarity Coefficient of 0.437 (Whole Tumor), 0.316 (Tumor Core), and 0.350 (Enhancing Tumor) on the test set, and an anomaly Detection Rate of 89.4% on the validation set. These findings highlight the potential of transformer-based unsupervised models to serve as scalable, label-efficient tools for neuro-oncological imaging.
